GW572016 For Treatment Of Refractory Metastatic Breast Cancer
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
This study was designed to determine the efficacy of an oral dual kinase inhibitor for the
treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a
refractory patient population.